|
 |
|
|||||||
|
|||||||||
DOI: 10.2337/dc05-1367
© 2006 by the American Diabetes Association
Pathophysiology/Complications |
IGF-Binding Protein-1 Levels Are Related to Insulin-Mediated Glucose Disposal and Are a Potential Serum Marker of Insulin Resistance
1 Diabetes Center, Department of Medicine, University of California, San Francisco, California
2 School of Life Science, Arizona State University, Tempe, Arizona
Address correspondence and reprint requests to Betty A. Maddux, University of California, San Francisco, 2200 Post, C415, San Francisco, CA 94143-1616. E-mail: bmaddux{at}itsa.ucsf.edu
OBJECTIVE—IGF-binding protein (IGFBP)-1 is negatively regulated by insulin. We determined whether the measurement of IGFBP-1 in serum is a useful marker of insulin resistance.
RESEARCH DESIGN AND METHODS—Twenty-three subjects underwent a euglycemic insulin clamp. Glucose disposal rates (M) were then correlated with measurements of IGFBP-1, fasting insulin levels, homeostasis model assessment (HOMA), and BMI.
RESULTS—IGFBP-1 levels more strongly correlated with M (R = 0.73) than the other parameters such as BMI or HOMA. The level of this protein decreased in individuals who became more insulin sensitive by exercise training.
CONCLUSIONS—These studies show a strong correlation between insulin sensitivity and the serum levels of IGFBP-1. These studies suggest, therefore, that measurement of this protein may be valuable in identifying those individuals with insulin resistance and those individuals who respond to interventional strategies.
Abbreviations: HOMA, homeostasis model assessment • IGFBP, IGF binding protein
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  K. E. Heath, J. Argente, V. Barrios, J. Pozo, F. Diaz-Gonzalez, G. A. Martos-Moreno, M. Caimari, R. Gracia, and A. Campos-Barros Primary Acid-Labile Subunit Deficiency due to Recessive IGFALS Mutations Results in Postnatal Growth Deficit Associated with Low Circulating Insulin Growth Factor (IGF)-I, IGF Binding Protein-3 Levels, and Hyperinsulinemia J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1616 - 1624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Semple, E. K. Cochran, M. A. Soos, K. A. Burling, D. B. Savage, P. Gorden, and S. O'Rahilly Plasma Adiponectin as a Marker of Insulin Receptor Dysfunction: Clinical utility in severe insulin resistance Diabetes Care, May 1, 2008; 31(5): 977 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vrieling, D. W Voskuil, J. M Bonfrer, C. M Korse, J. van Doorn, A. Cats, A. C Depla, R. Timmer, B. J Witteman, F. E van Leeuwen, et al. Lycopene supplementation elevates circulating insulin-like growth factor binding protein-1 and -2 concentrations in persons at greater risk of colorectal cancer Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1456 - 1462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. van Haeften, M. L. Zonderland, L. W.E. Sabelis, and J. van Doorn IGF-Binding Protein-1 Levels Are Related to Insulin-Mediated Glucose Disposal and Are a Potential Serum Marker of Insulin Resistance: Response to Maddux et al. Diabetes Care, June 1, 2007; 30(6): e53 - e53. [Full Text] [PDF]
|
|
|
|
|
|
B. A. Maddux, A. Chan, E. A. De Filippis, L. J. Mandarino, and I. D. Goldfine IGF-Binding Protein-1 Levels Are Related to Insulin-Mediated Glucose Disposal and Are a Potential Serum Marker of Insulin Resistance: Response to van Haeften et al. Diabetes Care, June 1, 2007; 30(6): e54 - e54. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |